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ABSTRACT 
The ability to combat infections through the generation of specific immune responses is 
critical to our survival. The immune system can react to and combat virtually any molecule 
presented to it, including those derived from our own body. The immune system can cause 
considerable damage to the structures it was designed to protect, thus causing autoimmune 
disorders. Examples include systemic lupus erythematosus, Sjögren’s syndrome, and 
rheumatoid arthritis, among many others. Many autoimmune disorders are caused in part by 
autoreactive antibodies produced by B lymphocytes, and targeting the activation of B 
lymphocytes thus forms a target for ameliorating disease. Better understanding of how B 
lymphocytes are activated is essential not only in order to limit autoimmune disease, but also 
in order to harness their capabilities in the context of generating successful vaccines.  
The work presented in this thesis deals with B lymphocyte activation in inflammation and in 
response to glycolipid antigens. The aim was to investigate how this activation is regulated 
and investigate the possibility of manipulating B cell activation in a desirable way. In papers I 
and III, mouse models were used to study the regulation of autoreactive and IgE-producing B 
lymphocytes using IL-18 to induce inflammation. In paper II, model glycolipid antigens were 
employed to investigate how different types of iNKT cell help affect the outcome for B cell 
activation, with the prospect of harnessing iNKT cell help as an adjuvants in vaccine therapy. 
In paper IV, the potential of using glycolipids in order to skew faulty B cell activation in 
inflammation was investigated.  
In paper I, iNKT cells were identified as regulators of autoreactive and IgE-producing B 
cells. Paper II defines quantitative and qualitative differences between cognate and 
noncogante B cell help provided by iNKT cells. Cognate iNKT cell help, compared to 
noncognate, expands a larger number of B cells producing the cytokine Interleukin 10. In 
paper III, mechanisms of iNKT cell regulation of B cell activation were investigated. 
Neutrophils were found to license iNKT cells to adopt a killing phenotype required to restrict 
B cell activation in sterile inflammation. In paper IV, B cell activation in inflammation was 
studied using exogenous glycolipid iNKT cell antigens. Serum antibody levels and germinal 
center formation were found to be increased in inflammation when iNKT cells were 
stimulated with glycolipids.  
In summary, the work presented in this thesis describes mechanisms controlling faulty B cell 
activation in inflammation. iNKT cells are critical in limiting B cell activation, and this was 
dependent on interaction with neutrophils. The interaction between neutrophils and iNKT 
cells plays a previously unappreciated role in the restriction of B cell activation, and thus 
serves as a potential target for new therapeutic strategies in autoimmune diseases. In addition, 
the use of glycolipids as vaccine adjuvants, or to target B cell activation is investigated.   
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1 INTRODUCTION 
Cellular organisms face constant challenges from other forms of life invading, in order to 
support their existence. Sometimes this is beneficial to the host, while other times it causes 
disease. Our immune system has evolved for millions of years in order to cope with both 
types of interactions. Through evolution, a highly intricate network of cells and organs has 
developed, appearing about 500 million years ago, to combat a diverse set of threats, extrinsic 
as well as intrinsic.  
Our immune system can be roughly divided in two main branches: The innate and the 
adaptive immune system. The former has evolved over time to make up a pre-formed, rapid 
defense system directed against a range of different pathogen- or danger-associated molecular 
patterns, including viral and bacterial particles, as well as deleterious components originating 
from our own bodies, such as dying cells. The second, adaptive, branch of the immune 
system evolves during the course of days to weeks. It resembles an incredibly accelerated 
form of evolution taking place within our own bodies, entailing molecular rearrangement of 
DNA to generate cellular receptors able to recognize foreign matter which have never before 
been encountered. The receptors are able to combat threats from the ever-changing challenges 
of pathogens, and long-lived cells are generated, enabling the immune system to remember 
the pathogen and combat it rapidly upon the next encounter, thus generating immunity. 
However, this impressive capacity of the adaptive immune system, to bind virtually any 
molecular structure, comes at a cost - autoimmunity.  As powerful as it is, and with the 
dangers associated with it, the adaptive immune system requires an abundance of regulatory 
mechanisms in order to keep it in check, so as to limit the destruction to pathogenic, rather 
than physiologic constituents of our bodies. 
The innate and adaptive immune systems are heavily interconnected, and they have co-
evolved to be able to combat infections together at different stages. The early stages are 
covered by the innate branch, while the adaptive immune system needs more time to evolve 
to become more efficient in fighting infection. However, it is clear that the innate system isn’t 
just a sentinel standing guard, but has a massive impact on the ensuing adaptive response.  
The work presented in this thesis is focused on cells of the immune system between the 
innate and adaptive branches. It investigates mechanisms of how these cells function to shape 
the outcome of inflammation in connection to diseases such as allergy and autoimmunity, as 
well as novel vaccine strategies. 
  
  
 2 
1.1 THE IMMUNE SYSTEM 
The cells and organs comprising the immune system have evolved in order to protect 
multicellular organisms from invading pathogens, e.g. viruses, bacteria and parasites. It is 
made up by a wide range of cells, which all play very different roles in the refined set of 
reactions that make up an immune response.  Given that a pathogen manages to trespass the 
barriers to infection made up by the skin and mucosa, sentinel cells present at these sites 
recognize the intrusion and act accordingly. These cells include dendritic cells (DCs), 
neutrophils and macrophages, which are able to identify foreign molecular entities, or 
antigens, and initiate a cascade of events to counteract the infection. They produce and 
excrete signaling proteins that activate and recruit (cytokines and chemokines, respectively) 
cells downstream in the immune response, including neutrophils and monocytes. The cells 
recruited to sites of infection begin to combat the infection locally, while DCs migrate from 
the site of infection to draining lymph nodes, where they initiate the adaptive immune 
response. The goal is for the DC to select and activate the right lymphocytes, which are the 
main characters of the adaptive immune system. T and B lymphocytes reside in lymph nodes 
and spleen, and express receptors capable of targeting virtually any antigen. However, it takes 
time to select the right lymphocyte for the job, and once the right lymphocyte is found some 
additional time is required for cellular expansion and improvement of its ability to target 
foreign antigen. Following a successful reaction to an invading pathogen, lymphocytes able 
to recognize and neutralize the pathogen are generated which survive as long-lived cells 
conferring immunity to the host, which is the goal for vaccination programs. 
1.2 INFLAMMATION 
The term inflammation is essential to the concept of immunology. In response to tissue 
trauma, e.g. if the skin breaks and there is a local infection, the tissue will respond by 
initiating an inflammatory response. We have all experienced this at some point in our lives, 
and the signs are probably recognized by all of us: Rubor, Dolor, Calor, and Tumor. These are 
the terms by which the inflammatory process was described about two thousand years ago by 
Celsus, and correspond to redness of the skin, pain, fever, and swelling, respectively.  
These hallmarks of inflammation can all be put into a functional context in order to explain 
and understand the process of inflammation. For example, when the skin breaks, cells 
proximal to the afflicted area will respond as to increase the blood flow to the area, resulting 
in heat and redness of the skin. It might seem counterproductive, but actually results in more 
cells of the immune system accessing the afflicted area. Cells of the vessel walls 
(endothelium) will also change so as to increase the permeability of vessels, enabling cells of 
the immune system to transmigrate across the vessel wall into the site of tissue damage, 
resulting in swelling of the tissue and again, more immune cells reaching the afflicted area[1]. 
Thus, inflammation serves as the kick-starter of the immune system in response to virtually 
any noxious stimulus, even non-infectious ones. However, the different constituents of the 
inflammatory tool box are very powerful, and can cause severely detrimental effects if not 
regulated tightly. There are numerous examples of diseases caused by inflammation, not only 
classical autoimmune diseases, where the body’s own organs are damaged, but also vascular 
disease[2] and cancer[3] are influenced by inflammatory processes. Inflammation is directed 
by a wide variety of molecules, soluble and present in cell membranes. These molecules 
include chemokines and cytokines. Interleukin-18 is a cytokine essential in immune cell 
activation and is one of the main players in inflammation and in this thesis. 
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1.3 INNATE IMMUNITY 
The division of our immune system into two main branches (innate and adaptive) is based on 
the mode of generation of the different receptors expressed by immune cells. Cells belonging 
to the adaptive immune system require extensive re-arrangement of their surface receptors in 
order to be able to perform their tasks. The receptors utilized by cells of the innate immune 
system are germline-encoded, meaning that we are born with this set of receptors which 
mediate protection, and hence, they are called “innate”. The cells and receptors that make up 
the innate immune system constitute our first line of defense against invading pathogens in 
the case a breach of the physical barriers formed by our mucosa and skin, and include 
neutrophils, DCs, macrophages, monocytes, neutrophils and Natural Killer (NK) cells. 
In case there is a breach of skin or mucosal barriers, innate immune cells have been equipped 
with tools able to identify the presence of foreign entities, enabling immediate recognition of 
infectious antigens. Throughout evolution, the innate immune system has selected recurring 
molecular patterns present in an abundance of microorganisms, which are the targets of 
receptors expressed by innate leukocytes. These recurring structures are referred to as 
pathogen-associated molecular patterns, or PAMPs. 
The receptors used by cells of the innate immune system to recognize PAMPs are pattern-
recognition receptors (PRRs), which are present both at the cell membrane and at intracellular 
compartments[4]. PRRs include toll-like receptors (TLRs), NOD-like receptors (NLRs), and 
C-type lectin receptors, among others. TLRs recognize a wide variety of PAMPs in the 
extracellular space as well as in the endosomal compartment. Examples of TLRs include 
TLR4, which binds lipopolysaccharide (LPS) present in in gram-negative bacteria [5], and 
TLR9, which binds unmethylated DNA[4]. While TLRs mainly recognize extracellular 
PAMPs, the NLRs are cytoplasmic receptors linked to assembly of a multi-protein complex 
known as the inflammasome, followed by downstream cytokine production[6]. 
As innate immune cells express germline-encoded receptors constitutively, they are directly 
activated following the encounter of PAMPs. They immediately act to combat the source of 
PAMPs – bacteria or viral particles, for instance. One way in which innate immune cells 
combat infection is to engulf the pathogen by means of phagocytosis. Other mechanisms 
employed by innate immune cells to fight pathogens will be discussed in later sections. Even 
though innate immune cells express PRRs able to recognize a wide variety of PAMPs, 
pathogens evolve rapidly and have developed ways to evade the innate immune system.  
1.4 ADAPTIVE IMMUNITY 
The innate immune system combats invading pathogens, but also activates the adaptive 
immune system. In essence, adaptive immunity is made up of the cells that are generated 
through a selection process effectively involving evolution in a micro-format – a quite 
extraordinary process in biology. The key cells in adaptive immunity are T and B 
lymphocytes. 
In the adaptive phase of an immune response, B and T lymphocytes are activated to undergo 
molecular programs enhancing their ability to fight infection. Unlike cells of the innate 
immune system, B and T lymphocytes express unique antigen-binding receptors (BCR and 
TCR, respectively), recognizing a distinct antigen (Figure 1). The receptor repertoire of 
lymphocytes is extensive, and it has been estimated that the T lymphocyte population can 
theoretically form up to 1015 different TCRs[7]. However, this is not actually achieved in a 
practical setting[8]. B and T cell receptors are generated by somatic rearrangement of the 
DNA of each lymphocyte through a process known as V(D)J recombination. During V(D)J 
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recombination, DNA strands open up and gene segments (labeled V, D, and J) are assembled 
to generate cell surface receptors capable of binding foreign and self-derived molecules. 
These functions are performed by RAG enzymes, and their expression is restricted to 
developing lymphocytes[9]. There is a limited number of V-, D-, and J-segments available 
for assembly, but the enzyme Terminal eoxynucleotidyl transferase adds random nucleotides 
in between segments assembled, in order to generate an incredible number of different 
receptor combinations. As the B and T cell receptor assembly process involves a certain 
amount of randomness, receptors recognizing molecular components derived from the host 
itself are generated, and for this reason, lymphocyte receptor selection is tightly 
regulated[10]. These include self-reactive proteins in membrane- and soluble form. 
The structures of completed B cell and T cell receptors are similar in that they both consist of 
two protein chains; heavy and light chain for B cells, and α/β chains for T cells. The receptors 
are generated while the cells are developing in the thymus (T lymphocytes) and in the bone 
marrow (B lymphocytes). Receptors are selected which can bind antigens presented at the site 
of development with a binding capacity, or affinity, not too high and not too low. This is in 
order to select BCRs and TCRs with the potential to bind antigens encountered in the future, 
while not self-reactive[11]. While the TCR serves as a solely a receptor conferring specificity 
to the T cell, the BCR serves the same function while also being able to be secreted once a B 
cell is activated. This soluble secreted form of the BCR is known as an antibody (or 
immunoglobulin, Ig) and is an essential product of the adaptive immune response which can 
confer immunity. The constant region of secreted antibodies can be of different subcategories, 
known as isotypes. Different isotypes serve different purposes, e.g. IgA is present at high 
proportions in tear ducts and intestine, while IgG is present in the blood. Thus, the same 
specificity derived from the variable region can perform different functions through changing 
the immunoglobulin isotype. Antibodies serve several functions, including binding to 
molecular structures and recruiting immune cells, conferring immunity to infection, or 
causing pathology in autoimmunity. 
Figure 1. The structure of T and B lymphocyte receptors. BCRs and TCRs are similar in 
that they both are formed by two protein chains. However, only the BCR is found in a 
secreted form and is then referred to as an antibody. If an antibody was the size of an adult 
human, the cell membrane of a B cell would take up an area corresponding to three times 
the size of Central Park, NYC. 
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1.5 ANATOMY OF THE IMMUNE SYSTEM 
As mentioned above, the immune system is comprised by a large variety of cells located all 
over the body, since we require protection from pathogens everywhere as all of our tissues 
represent potential sites of infection. The immunological organs are generally divided into 
primary and secondary organs, and the initial hematopoiesis takes place in primary lymphoid 
organs. Included in the category of primary lymphoid organs are the thymus and the bone 
marrow (Figure 2). Some developmental steps required for proper leukocyte generation do 
not take place in primary lymphoid organs, but require leukocytes to migrate to secondary 
lymphoid organs. These organs include the spleen, lymph nodes, mucosa-associated 
lymphoid tissue, tonsils, and several other sites present in many tissues. 
1.5.1 The bone marrow 
The bone marrow is a non-solid organ mainly found in the epiphysis part of the long bones 
(e.g. the femur). It is the production site of an impressive number of immune cells, including 
5x1012 red blood cells per day. Importantly, the bone marrow is the site of granulocyte and 
lymphocyte formation.  
The bone marrow is the site for several early steps of B lymphocyte development including 
generation of the antigen-binding B cell receptor (BCR) [12]. For most developing B cells, 
the final maturation steps and adopting a mature phenotype take place in the spleen [13, 14]. 
The maturation stages of B cell development can be delineated according to differential 
expression of a set of cell surface proteins[15]. The B cell maturation sequence in the bone 
marrow is crucial to form a normal B cell repertoire as well as to limit the formation of self-
reactive B cells[10]. The program includes heavy-chain gene rearrangement in pro-B cells 
Figure 2. Anatomy of the immune system.  
For the National Cancer Institute © 2007 Terese Winslow, U.S. Govt. has certain rights 
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followed by selection and proliferation of pre-B cells which express appropriate BCRs. This 
is followed by light-chain rearrangement and further differentiation into immature T1 and T2 
B cells [15, 16]. 
1.5.2 The thymus 
The thymus is the site of maturation for T lymphocytes. It is located in the mediastinum, 
under the sternum and in front of the heart. The thymus is an organ which in time atrophies, 
and after the neonatal pre-adolescent phase of life, it is replaced by fat, with some residual T 
cell development lingering [17]. Lymphocytes precursors destined to develop into T 
lymphocytes are initially generated in the bone marrow, followed by migration to the thymus 
where they undergo a multistep selection program, in order to generate a desirable repertoire 
of T lymphocytes[11]. The generation of T cells in the thymus is critical in order to combat 
infection[18] as well as to reject foreign tissue and grafts, as famously shown with the 
athymic “Vacanti” mouse, growing a prosthetic ear on its back [19].  
T cell development taking place in the thymus is essential for the formation of T cells, and 
without a thymus, T cells generally will not form. In the thymus, there is a unique expression 
pattern of a range of host-derived molecules, enabling negative selection of T cells which are 
too self-reactive[11]. This function is exerted by stromal cells known as thymic epithelial 
cells. T cells go through a double-negative stage, followed by a CD8+ single-positive and 
CD4+ CD8+ double-positive stage. T lymphocytes then differentiate into either CD8+ T 
cells, crucial in combating intracellular infections[20], or CD4+ T cells, which are the 
orchestrators of the immune system[21]. The thymus is also the site for iNKT development, 
which constitute an innate-like subset of T cells. iNKT cells, unlike other T cell subsets, do 
not recognize peptide antigens, but rather glycolipid molecules. In addition, they are not 
selected by cortical epithelial cells in the thymus, but rather by other double-positive 
thymocytes [22, 23].  
1.5.3 The spleen 
The spleen is the largest secondary lymphoid organ in humans, weighing about 150-200 
grams and is located in the upper left quadrant of the abdomen, directly beneath the 
diaphragm. It has a wide range of functions, including storage of red blood cells, neutrophils 
and platelets, hemoglobin metabolism and antibody production[24]. Splenectomized 
individuals have an increased predisposition to certain bacterial infections, such as 
Streptocuccus pneumoniae[25], indicating the importance of this organ in combating blood 
borne pathogens[26]. 
Histologically, the spleen is divided into two distinct compartments – the red pulp and the 
white pulp, which are functionally and morphologically separate (Figure 3). The spleen is a 
highly vascularized organ and blood enters through the splenic artery and divides into smaller 
trabecular arteries which feed white pulp capillary beds. Some capillary beds end up in the 
marginal sinus, between the white pulp and the marginal zone (MZ), while others drain in the 
marginal zone itself. A few capillary beds extend beyond the white pulp and terminate in the 
red pulp of the spleen[27]. Unlike lymph nodes, there are no afferent lymphatic vessels 
leading to the spleen. Thus, this organ monitors the blood and performs janitorial tasks 
required in this tissue.  The spleen contains about one-fourth of the body’s lymphocytes, 
including several specialized cell types, which monitor and respond to sepsis, for instance.  
The red pulp is the main site for removal of senescing erythrocytes and iron recycling. To 
uphold this function, there are numerous macrophages present in the red pulp, which take up 
old erythrocytes through phagocytosis. The red pulp also serves as a lodging site for 
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plasmablasts and plasma cells[24]. Following B cell activation by antigen, B cells transit via 
the red pulp and remain there temporarily while they produce and secrete antibodies allowing 
rapid entry into the bloodstream.  
The white pulp is subdivided into follicles, periarteriolar lymphoid sheaths (PALS), and the 
marginal zone. These subcompartments contain B cells, T cells, macrophages, DCs, as well 
as other cell types. In the PALS, also known as T-cell zones, T cells constantly monitor 
passing cells, including DCs and B cells, in order to coordinate immune responses[28]. In the 
follicles, or B-cell zones, clonal expansion of B cells takes place following activation by 
antigen, leading to somatic hypermutation (SHM) and isotype switching[29].  
The marginal zone is situated at the interface of the red pulp with the PALS and follicles. As 
the marginal zone contains specialized cells restricted to this area, the marginal zone is 
generally regarded as a separate compartment, rather than part of the white pulp. In the 
marginal zone there are at least two subsets of specific macrophages - marginal-zone 
macrophages and marginal-zone metallophilic macrophages[28], performing functions such 
as scavenging and iron recycling. Marginal zone B cells are also uniquely found in the 
marginal zone of the spleen. They shuttle between the marginal zone and follicles in order to 
transport and deposit antigen to the T and B cell areas of the white pulp[30, 31]. MZB cells 
are sentinels capable of rapidly responding to blood-borne antigens[32]. They express very 
high levels of the antigen-presenting molecule CD1d, compared to other leukocytes [33].  
1.6 B CELLS 
The concept of separate B cell and T cell lineages was first described by Max B. Cooper in 
the 1960’s, although essential products of their activation - antibodies - have conceptually 
been around since the late 1800s[34]. B cells are mostly known for making antibodies, and 
this is indeed one of the major functions of this cells type. However, B cells serve other 
capabilities as well, including production of cytokines[35] and antigen presentation[36]. 
Every B cell expresses a B cell receptor unique to that particular B cell, which is generated 
during the development of the B cell. Cytokines produced by B cells help direct immune 
Figure 3. Histology of the 
spleen. 
Spleen section from a 
CXCR6-GFP reporter 
mouse, stained for CD1d 
(blue - MZB), Ly6G (red - 
neutrophils), and B220 
(white – FOB). CXCR6 is 
reported in green (iNKT).  
RP – Red pulp 
B – Follicle (B cell area) 
T – PALS (T cell are) 
MZ – Marginal zone 
T-B – T zone-B-zone border 
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responses and are important in the development of lymphoid organs[37]. Thus, B cells 
perform a wide variety of functions in inflammation and immune responses.  
1.6.1 B cell development and subsets 
During B cell development, the majority of precursors will not survive to maturity. It has 
been estimated that as much as 95% B cell precursors do not make it to the mature naïve 
stage of B cell development[10]. In the bone marrow, cells that are destined to become B 
cells initiate immunoglobulin heavy-chain rearrangements, ultimately generating a BCR 
which serves as the blueprint for secreted antibodies later on, following activation of the B 
cell[12]. In B cell development, there are two major checkpoints for negative selection of B 
cells. One central checkpoint in the bone marrow between early immature and immature B 
cells, and one peripheral checkpoint between the transition from new emigrant and mature 
naïve B cells[10]. B cells which generated strongly self-reactive BCRs are negatively selected 
and undergo clonal deletion and cell death[38].  
Successful BCR rearrangement in the bone marrow generates a B cell which matures further, 
through transitional 1 and 2 B cell stages (T1 and T2, respectively). The T1 developmental 
stage for a B cell is characterized by the inability to recirculate and these B cells are found in 
the spleen and bone marrow[15]. In the following T2 stage, B cells are able to recirculate and 
are localized in follicles, while still expressing markers for immaturity. Most T2 cells mature 
into follicular B cells in the spleen, while about one-quarter of T2 cells acquire this phenotype 
in the bone marrow[39]. T2 cells migrating from bone marrow to spleen in order to mature 
further can also mature into Marginal Zone B cells (MZBs), which make up a distinct subset 
of B cells.  
The mature pool of B cells is generally divided into three different subsets: Follicular B cells 
(FOB), Marginal zone B cells (MZB), and B1 cells[40]. These cover different functional 
aspects in antibody-mediated protection against noxious stimuli [12, 32, 41]. The FOBs make 
up the majority of mature naïve B cells, and are the ones that generally come to mind when 
discussing B cells. They are recirculating and considered the main B cells executing the 
classical thymus-dependent antibody-mediated immune response. In contrast to FOBs, MZBs 
are rather sessile in rodents, and found in the marginal zone of the spleen. MZBs are more 
innate-like, and are rapidly activated to produce antibodies, compared to FOBs[32]. Finally, 
B1 cells are located in the pleural and peritoneal cavities, and are also considered innate-like 
B cells, as they generally are easily activated and produce antibodies which tend not to be a 
product of SHM but rather, germline-encoded[41, 42].  
Even in the absence of immunization, there are antibodies formed, called natural antibodies 
(nAb). nAbs are capable of binding antigens present in pathogens, for instance, bacterial 
polysaccharides. nAbs often cross-react with host-derived antigens, including DNA and 
phosphorylcholine, as well antigens not present in the host, e.g. 4-hydroxy-3nitrophenyl 
(NP). B1 and MZBs are believed to be responsible for the production of nAbs[43]. 
1.6.2 B cell activation 
In T cell-dependent antibody responses, a mature B cell encounters its cognate antigen and is 
activated through BCR engagement. There are different ideas of exactly how this occurs, but 
current models propose that BCR engagement leads to receptor clustering and downstream 
signaling of intracellular molecules [44-46]. Depending on the context, and what stage the B 
cell is at during its lifespan, B cell activation will have different outcomes[47]. Germinal 
center (GC) and extrafollicular foci formation are the two major pathways taken by antibody 
producing B cells. One of the primary determinants for choosing between the GC and 
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extrafollicular foci is the strength of the interaction between the B cell receptor and its 
antigen[48]. B cells can also be activated to produce another class of proteins – cytokines[49]. 
1.6.2.1 Germinal centers 
Germinal centers (GC) are structures found in the spleen and lymph nodes formed by 
activated B cells which undergo selection events and are stimulated to produce high-affinity 
antibodies[29]. The GC is a hallmark structure of immune system activation, as they 
participate in the generation of immunity against pathogens. However, the very process of 
generating high-affinity antibodies involves dangerous downsides: malignant transformation 
of B cells[50], and important to this thesis – the generation of self-reactive antibodies[51].  
The germinal center can be clearly identified in histological preparations of lymphoid tissue. 
Structurally, the GC is comprised of a dark zone and a light zone. These zones demarcate 
areas with different functions in B cell activation, necessary to generate high-affinity 
antibodies[29]. Following antigen engagement by B cells and stimulatory signals delivered 
by CD4+ T cells at the T-B border in secondary lymphoid tissues (Figure 3), B cells 
accumulate in primary follicles to form germinal centers[29]. In the germinal center, B cells 
are selected and undergo immunoglobulin gene rearrangement programs, known as somatic 
hypermutation (SHM) and class-switch recombination (CSR). These gene-modulatory 
processes are required in order to generate high-affinity antibodies[52, 53] of different isotype 
classes[54], respectively. When a B cell is activated to form a GC, it induces the enzyme 
activation-induced cytidine deaminase (AID), which introduces random mutations in the 
antigen-binding site of the BCR. Sometimes this generates a BCR with higher binding-
capacity, or affinity, for the antigen that induced B cell activation, while other times the 
affinity is lowered by a mutation. In the former case, the B cell will be selected and receive 
survival signals from follicular dendritic cells and T follicular helper cells (TFH), while the 
latter case will result in induction of apoptosis in the B cell. The insertion of random 
mutations into the antigen-binding site of the BCR comes with the potential of generating 
self-reactive immunoglobulin[55]. GC B cells upregulate Fas, a protein inducing apoptosis 
when it is engaged by FasL[56]. GC B cells with high affinity for the antigen inducing the 
GC will receive supporting signals from TFH cells and upregulate anti-apoptotic proteins. Fas-
FasL regulation is critical to the restriction of GC B cell formation[57], and a lack of FasL 
results in increased GC formation and production of autoreactive antibodies[58-60]. 
1.6.2.2 Extrafollicular foci 
The majority of the early protective antibodies in an immune response derive from the 
extrafollicular foci response[61]. In the spleen, extrafollicular foci formation takes place in a 
different microanatomical compartment compared to the germinal center response. 
Extracellular foci are formed by antibody-forming cells (AFC) in the red pulp area, at the 
bridging channels in proximity of PALS and B cell areas. 
Following B cell activation by antigen, the B cell migrates towards the T cell zone of the 
spleen where they present antigen to CD4+ T cells from which they receive signals to 
produce Ig heavy chain transcripts [62]. Next, they enter the cell cycle, upregulate the 
essential transcription factor Blimp-1[63], proliferate, followed by exit to the red pulp 
area[61]. Here, the activated B cell, now called plasmablast, undergoes class switch 
recombination and starts secreting antibody. B cells undergo somatic hypermutation outside 
germinal centers [64], and therefore, these structures also present potential sources of self-
reactive antibodies. 
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1.6.2.3 Cytokine production 
A more recently described feature of B cell activation is the production of cytokines capable 
of directing immune system activation[65]. B cells have been identified as producers of a 
wide range of cytokines. These affect several crucial aspects of the immune system, including 
lymphoid tissue development and organization[66], dendritic cell cytokine production[67, 
68], polarization of CD4+ T cells, and negative regulation of immune responses. The concept 
of B cells negatively regulating immune activation is not new, and the idea of B cells acting 
in a suppressive manner was suggested already in the 1970s[69, 70]. However, the 
mechanisms of B cell suppression were described fairly recently, with the first papers 
identifying B cell provision of immune regulatory IL-10 early this millennium[71-73].  
Unlike the T cell branch of lymphocytes, no clear consensus regarding the phenotype of 
regulatory B cells has been established. For B cells, all of the following subsets have been 
identified as capable of producing regulatory cytokines; T2-MZP cells[74], CD5+ CD1dhi B 
(B10) cells[75], MZB cells[76], CD138+ plasma cells[77], and others are being investigated. 
To this day, despite considerable efforts, no study has been able to identify a lineage-specific 
marker for regulatory B cells. As it seems, any B cell can potentially adopt a B regulatory 
(Breg) phenotype, depending on local stimuli present in the microenvironment[65]. Thus, it 
seems like the primary factor affecting whether B cell will adopt a regulatory phenotype or 
not, is the environment in which it finds itself, prompting further investigation of the different 
types of stimuli capable of inducing this regulatory phenotype. TLR stimuli and CD40-
mediated activation are the signals that have been characterized most extensively[35], while 
recent studies have shown that cytokines are also capable of inducing Breg cells producing IL-
10[78].  
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1.7 T CELLS 
T lymphocytes act as conductors of essentially all immune reactions, but also function as 
effector cells, directly combating pathogens as well as dangers arising from our own bodies – 
e.g. cancer[20]. The importance of T cells can be grasped when considering that the global 
health issue of AIDS arises due to a virus capable of eliminating a subpopulation of these 
cells[18]. T lymphocytes undergo a strict selection process through which they acquire a 
unique antigen-binding T cell receptor (TCR). This receptor is able to recognize antigen, self- 
and foreign, in the context of a family of proteins known as the major histocompatibility 
complex (MHC)[79]. Molecules presented to T cells in the context of MHC derive from all 
cellular compartments, so as to give the T lymphocytes an idea of what is going on inside 
other cells of the body[80]. There are two groups of MHC molecules – MHC class I (MHC I) 
and MHC class II (MHC II). MHC I molecules can be expressed by virtually any cell, and it 
is through the interaction between MHC and TCR that T cells are able to recognize infected 
or malignantly transformed cells and discriminate them from healthy, non-infected cells. 
Several different categories of T cells have been identified, including conventional TH1, TH2 
and TH17 cells, regulatory T cells (including Foxp3+ TREG), PD-1+ CXCR5+ TFH cells, the 
innate-like iNKT cells, and others.  
1.7.1 Regulatory T cells (TREG) 
T cells not only act as to amplify immune activation. A subset of regulatory T cells (TREG) 
inhibit the actions of other immune cells. Their importance of TREGS is illustrated by the fact 
that mice lacking them succumb to autoimmune disease within months [81], and people 
deficient in TREG cells are afflicted with severely debilitating diseases [82]. These TREG cells 
can be induced in peripheral organs as well as lineage-committed at an early stage of T cell 
development[83]. The transcription factor Foxp3 serves as a marker for TREG cells, and is 
required for regulatory functions[84]. A subset of TREG cells localize to B cell follicles in 
order to exert their regulatory functions and express CXCR5 and PD-1[85]. TREG cells 
function by producing cytokines such as IL-10 and TGFβ which dampen immune 
responses[86]. 
1.7.2 T follicular helper cells (TFH) 
TFH cells are required for the development and function of germinal centers[87]. In the 
germinal center, B cells bind antigen which they present to TFH cells which, in turn, provide 
help to the B cell. These helping signals provided by TFH cells are critical to the survival and 
proliferation of GC B cells. The GC B cells with high antigen affinity receives supporting 
signals from TFH cells, followed proliferation in the germinal center and somatic 
hypermutation in order to mutate the BCR, to further increase antigen affinity[88, 89].  TFH 
cells can be defined by means of several different markers, including CXCR5, BCL6, PD-1, 
CD4, all of which are important to the proper function and migration of TFH cells[90]. The 
help signals provided by TFH cells include soluble molecules and receptors expressed on the 
cell surface. Major help molecules identified so far include IL-21, IL-4 and CD40L. These 
molecules provide survival and proliferation signals to B cells, and also stimulate class switch 
recombination[90].  
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1.7.3 iNKT cells 
Invariant Natural Killer T (iNKT) cells form a subgroup of T cells which operate on slightly 
different premises than conventional T lymphocytes. They express a TCR formed by a very 
limited set of V(D)J regions, which in mice are comprised of the Vα14Jα18 chain, combined 
with a Vβ7, Vβ8.2 or Vβ2 chain[91, 92]. This restricts the set of antigens which can be 
recognized by the iNKT cells. While conventional T lymphocytes recognize peptide antigens 
in the context of highly polymorphic MHC molecules, iNKT cells are selected to recognize 
glycolipids in the context of the non-polymorphic MHC I-like molecule CD1d[92]. In 
humans, there are several different CD1 molecules presenting antigen to CD1-restricted T 
cells[93]. In the developmental stages of iNKT cells, they are not selected by thymic 
epithelial cells expressing MHC molecules, but rather by other thymocytes which express 
CD1d[22]. They are also dependent on other cytokines than conventional T cells for their 
maturation and maintenance[91]. iNKT cells can be identified with tetrameric CD1d protein 
loaded with glycolipid ligands like α-Galactosylceramide (αGalCer)[94] In the spleen, the 
expression of CXCR6 identifies mostly iNKT cells[95].  
1.7.4 iNKT cell activation 
iNKT cells are able to act rapidly and potently when stimulated[96]. iNKT cells resemble 
memory T cells in that they are rapidly activated and express receptors which normally 
distinguish antigen-experienced T cells[91]. Their threshold of activation is also lower than 
for conventional T cells, making iNKT cell activation slightly more versatile [97]. 
Conventional T cells undergo phenotypic and functional changes when they become memory 
T cells, which partly form the basis of immunity. iNKT cells have been assumed not to form 
memory cells. However, iNKT cells expressing killer lectin-like receptor subfamily G, 1-
positive (KLRG1) were shown to possess memory qualities, conferring long-lasting 
antitumor capability [98].  
While clonal expansion and cytokine expression by conventional T cells requires several 
signals, including TCR engagement and co-receptor stimulation, iNKT cells can be activated 
solely through their TCR, cytokine receptors, or a combination of the two[97]. The way in 
which the iNKT cell responds will depend on the combination of signals present, and site of 
these stimuli [96, 99]. In the context of an infection, the lipid presented to iNKT cells by 
CD1d can be derived from the invading pathogen[100], but iNKT cells are also inherently 
autoreactive[42]. There are several glycolipids identified able to activate iNKT cells, and 
depending on their structure they generate slightly different immune responses. Examples 
include αGalCer[101], GSL-1[102] and OCH[103], which all induce different cytokine 
outputs when activating iNKT cells. 
The most dramatic effect seen following iNKT cell activation with glycolipids is a massive 
production of cytokines. The type and amount of cytokine produced depends on the 
activating ligand, but the main ones are IL-4[104] and IFNγ[102]. However, iNKT cells are 
able to produce a much wider range of cytokines (e.g. IL-2, IL-3, IL-6, IL-10, IL-21, GM-
CSF [105]), indicating that this feature of iNKT cell activation is highly context-dependent. 
The context-dependent activation of iNKT cells has been further corroborated in vivo[99], 
and it has been suggested that different lineages of iNKT cells are responsible for the 
production of different cytokines at steady state[106, 107]. 
The role played by iNKT cells in B cell responses to foreign antigens recently took dramatic 
turn. Two studies using different approaches identified a B cell-helping role of iNKT cells 
[108, 109]. iNKT cells adopted a follicular helper phenotype, including expression of CXCR5 
and PD-1[109]. Importantly, iNKT cells were essential in providing IL-21[108], a cytokine 
 13 
 
critical to support antibody production and isotype switching by B cells[110]. In mice 
injected with αGalCer, a proportion of iNKT cells adopt a phenotype resembling TFH cells. 
There are two ways in which an iNKT cell proved help to B cells; cognate and noncognate. 
Cognate iNKT cells help takes place when the B cell directly provides antigen in the context 
of CD1d, and receives activating signals from the iNKT cell. For noncognate help, another 
cell presents antigen to the iNKT cell, which gets activated and activates the B cell without 
necessarily interacting directly[97]. 
1.8 NEUTROPHILS 
We have all seen neutrophils at some point in our lives - dead or dying neutrophils form the 
major cell constituent of pus. Neutrophils are typically the first leukocyte responders in 
response to infections, and their role in the initial phase of an immune response has been 
recognized for a very long time. Neutrophils have a very high turnover rate, with a bone 
marrow output of about 1011 cells per day[111]. In mice, neutrophils constitute 10-25% of 
circulating leukocytes while in humans, the proportion is considerably higher at 50-
70%[112]. Neutrophils have a distinct phenotype, with a multi-lobular nucleus[113] and high 
content in granules containing pro-inflammatory proteins[114] serving a wide range of 
functions[115]. Several of the proteins have been identified as proteases, capable of 
degrading tissue components in order to allow for neutrophil movement to inflammatory 
sites, while others are capable of directly killing bacteria[114, 116].  
It is well-established that neutrophil localization to inflammatory sites is required following 
infection in order to efficiently clear infection. The classical view of neutrophils regard their 
sole mission as engulfing pathogens followed by neutrophil death, and this is indeed a part of 
their function[117]. However, recent advances within the field have shown that neutrophils 
have in their arsenal a much more sophisticated set of tools than previously expected[118].  
1.8.1 Neutrophil development 
Under homeostatic conditions, neutrophils develop exclusively in the bone marrow and, 
unlike T and B lymphocytes, they are normally not released from the bone marrow before 
maturity [119]. Being part of the myeloid lineage of cells, neutrophils develop from a 
common myeloid progenitor stem cell in the bone marrow followed by a series of 
developmental steps on the way to becoming a mature neutrophil[120]. CXCR4 is the main 
chemokine receptor for the chemokine CXCL12, and these molecules are expressed by 
neutrophils and bone marrow stromal cells (e.g. osteoblasts, endothelial cells), 
respectively[121]. This axis is important in the life of a neutrophil, as the expression level of 
CXCR4 by neutrophils increase during their lifespan, thus homing ageing neutrophils back to 
the bone marrow for clearance[121, 122].  
Compared to T lymphocytes, neutrophils have classically been regarded as a far more 
homogenous population of cells, where distinctions analogous to TH1 and TH2 are not 
applicable. Recently however, there has been a renaissance within the field of neutrophil 
biology, describing several different subtypes of neutrophils [123]. Evidence has accumulated 
supporting the notion that different neutrophil subsets or even lineages have distinct functions 
in infection[124], inflammation and cancer immunology[125]. However, it remains to be 
demonstrated if the different neutrophil populations demonstrated so far represent different 
lineages, or whether they are rather a product shaped by the course of inflammation.  
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1.8.2 Neutrophil activation 
When inflammation is triggered, molecules are released from the inflicted tissue in order to 
recruit leukocytes, including neutrophils, to help fight the triggering event. Neutrophils are 
activated by a wide range of stimuli since they express all TLRs described, except for TLR3 
[126]. They also express a G protein-coupled receptor called formyl peptide receptor 1, 
important in sensing sterile inflammatory components[115, 127]. Once activated, dramatic 
changes take place, concerning many different aspects of neutrophil biology. One crucial 
parameter is their lifespan. The average lifespan for neutrophils in mice has been estimated to 
hours[128], but increase several-fold i inflammation, ensuring that activated neutrophils are 
present at the inflammatory site. Activation by bacterial products, as well as various 
cytokines and growth factors can all have this effect[129]. Another important function of 
neutrophils is cytokine production and release, and they can produce a roster of cytokines 
bested by few other leukocytes[130]. The cytokines they produce include IL-1β, IL-18, 
BAFF, IL-4, IFNγ, and many more[115]. Cytokine contribution by neutrophils can be 
controlled at the transcriptional level (mRNA transcription), translational level (e.g. through 
targeting of microRNA), and at the level of secretion of protein [131].  
Neutrophils can also release intracellular components to form structures called neutrophil 
extraceullular traps (NETs)[132]. These structures have since their discovery in the early 
2000s been the focus of intense research to further our understanding regarding their 
function[133]. NETs are formed following neutrophil expulsion of nuclear components, such 
as DNA and histones, which are covered by proteins derived from neutrophil granules, such 
as neutrophil elastase (ELA2)[132, 134] and matrix metalloproteinase 9 (MMP9)[132]. 
Several different pathogens have been shown to be trapped by NETs, including S. aureus, S. 
enterica, C. albicans, and others [132, 134, 135]. Trapping of microbes in NETs promote the 
action of proteins derived from neutrophil granules which act to lyse the trapped bacteria, 
which are then disposed of [115]. Although NETs seem beneficial in settings of infection, 
they contain several self-derived molecules, including antigens forming the main targets of 
autoreactive antibodies which underlie pathology in diseases such as SLE and Sjögren’s 
syndrome, including DNA and histones[136]. Thus, NETs can potentially contribute to the 
development and propagation of autoimmune disease [137, 138]. 
Another aspect of neutrophil functionality is their capacity to present antigen to other cells of 
the immune system. The role of neutrophils as antigen presenting cells has been largely 
overlooked in the past. However, neutrophils express MHC II, like professional antigen 
presenting cells[139]. In bone marrow chimeric mice it was demonstrated that neutrophils 
can be activated in a CD1d-dependent way, to produce IL-10[140]. However, little is known 
about the expression of this group of antigen-presenting molecules on neutrophils. 
Early neutrophil activation can be evaluated by monitoring the expression of cell surface 
proteins. These proteins include molecules critical to the function of neutrophils like CD11b, 
CD18 and CD62L. CD11b and CD18 are integrins which mediate firm adhesion to 
endothelium and are required for neutrophils to enter tissues[141]. CD62L, or L-selectin, 
plays a role in tethering and rolling of neutrophils before crossing vascular endothelium to 
sites of inflammation[142]. Following activation by chemokines, neutrophils rapidly shed 
CD62L [143]. 
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1.9 IL-18 AND THE INFLAMMASOME 
Cytokines are critical in the orchestration of immune responses, both with respect to initiating 
an inflammatory response and triggering leukocyte activation, as well as inducing 
tolerogenic, immune-dampening responses[144]. Within the larger family of cytokines, 
subgroups of related proteins have been established. In this thesis, one of the main characters 
– Interleukin-18 – belongs to the IL-1-family of cytokines[145]. IL-18 is constitutively 
expressed in several different cell types (e.g. DCs, macrophages) and requires post-
translational processing before becoming biologically active [146]. This is accomplished by a 
multiprotein complex known as the inflammasome[6]. Known inducers of inflammation such 
as asbestos, aluminum complexes, toxins, bacteria, viruses can all induce inflammasome-
assembly [147-150], and thus, the cleaving of IL-18 into its biologically active form. 
Inflammasomes can be assembled and transferred through the extracellular space to another 
cell and exert its function in the recipient cell [151, 152].  
There are a number of different inflammasomes, differing in the type of stimuli inducing 
them, and their downstream products[6]. Nod-like receptor 3 (NLRP3) is an extensively 
studied inflammasome activated by viruses[148], bacteria[147], fungi[153], toxins[150], and 
dying cells[154]. NLRP3 oligomerizes when it senses intracellular danger signals (Figure 4). 
Subsequently, the adaptor protein apoptosis-associated speck-like protein containing a 
caspase recruitment domain (ASC) is recruited and incorporated as another domain of the 
assembling inflammasome[155]. The ASC domains recruit pro-caspase-1, which is cleaved 
and activated to caspase-1, generating a mature inflammasome[156]. Caspase-1 is a cysteine 
protease that cleaves pro-IL-18 into biologically active IL-18[146]. 
  
Figure 4. Inflammasome activation and assembly. Formation of the multiprotein complex 
NLRP3 is induced by several different stimuli, including toxins, asbestos and pathogen-
associated molecular patterns. Downstream of Caspase-1 activation, pro-IL-18 is cleaved to 
produce biologically active IL-18. 
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1.9.1 IL-18 in immune activation 
In general, IL-18 functions as to enhance innate and adaptive immune responses. This 
enhancement includes the upregulation of MHC molecules and migration of leukocytes[157]. 
The biological effects of IL-18 are mediated through binding of IL-18 to the IL-18 receptor 
(IL-18R), which is formed by a heterodimer consisting of the IL-18Rα and ß chains [158, 
159]. This is achieved by inflammasome-cleaved IL-18 binding to non-occupied IL-18Rα on 
cells expressing this receptor, followed by recruitment of the IL-18Rß chain, which does not 
bind the cytokine but is required for intracellular signaling[160, 161].  
IL-1 and IL-18 are similar in that they both make use of the myeloid differentiation factor 88 
(MyD88)-signaling pathway [162]. MyD88 functions as an adaptor molecule in TLR- and IL-
1R signaling pathways[163], and for the IL-18 pathway, it anchors IL-1R-associated kinases 
(IRAKs) to the protein complex established at the cell membrane[164]. Once phosphorylated, 
IRAKs bind tumor necrosis factor receptor-associated factor 6 (TRAF6) [165], which is in 
turn thought to phosphorylate NFkB-inducing kinase (NIK)[166]. NIK phosphorylates 
Inhibitor of κB kinases (IKK) which are thus targeted for destruction via ubiquitination and 
proteasomal degradation, resulting in a lack of inhibition of the NFκB protein which is set 
free to enter the nucleus and alter gene expression of downstream targets such as e.g. 
IFN.  
IL-18 is a very potent cytokine requiring multiple regulatory mechanisms avoiding improper 
and detrimental activation. One of these is found in the intrinsic lack of biological activity of 
IL-18 not yet processed by the inflammasome. Another mode of regulation is the production 
of regulatory proteins. IL-18 binding protein (IL-18BP) is constantly being produced and is 
present in serum of healthy humans at a 20-fold molar excess compared to IL-18[168]. IL-
18BP binding to IL-18 effectively inhibits the actions of IL-18, thus protecting the body 
against detrimental effects of untimely secretion of biologically active IL-18[169]. 
Traditionally, cytokines have been divided into TH1- or TH2-type cytokines, based on their 
functions enhancing T helper responses[170]. The discovery of alternative cytokines, which 
do not allow such classification[144] has made it increasingly complicated to describe and 
model the functions of individual cytokines according to TH1- or TH2-properties. IL-18 is one 
of those cytokines not allowing simple classification, but exerts functions dependent on the 
inflammatory milieu [171, 172]. For instance, if co-administered with IL-12, IL-18 enhances 
a TH1-skewed inflammatory response with production of IL-13, while IL-18 alone stimulates 
IL-4 release and a TH1-response [172]. The functions of IL-18 have been tied to pathological 
processes in a multitude of autoimmune and inflammatory disease, including Sjögren’s 
syndrome, systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis 
(RA) and others[157, 173]. It has been shown that IL-18 levels in serum or in the target organ 
correlate with disease severity in patients suffering from SLE[174], MS[175], and RA[176, 
177].  
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1.10 SYSTEMIC LUPUS ERYTHEMATOSUS 
SLE is a potentially fatal autoimmune disease afflicting about 1 in 2,500 people, and the 
prevalence is highly variable depending on geographical location and ethnicity[178]. An even 
stronger factor than ethnicity is sex, as about 90% of SLE patients are women. A hormonal 
component is suggested to be causing this difference while underlying mechanisms remain 
unclear[179]. SLE is highly variable in its manifestations, and several diagnostic criteria need 
to be fulfilled for accurate diagnosis. Among these are clinical symptoms, including arthritis, 
rashes, photosensitivity, as well as laboratory tests of kidney and liver function, and the 
presence of autoantibodies in serum[180]. Clinical symptoms of SLE are caused by the 
presence of antibodies binding self-antigens, which form immune complexes deposited in 
fine vessels where they initiate inflammation and cause disease[181]. This feature is a 
hallmark of SLE, where immune complexes usually end up in the kidneys causing 
nephritis[182]. There is a range of antigens to which autoantibodies bind, but DNA is remains 
the essential biomarker for SLE[183]. Patients usually suffer from disease flares, where 
sudden outbursts of severe disease can be triggered by environmental agents, e.g. UV-
light[184].  
There is no cure for SLE, but there are several therapeutic strategies employed in order to 
ameliorate disease progression as well as symptomatic treatment[185]. These include non-
steroidal anti-inflammatory drugs for mild disease, and corticosteroids and cyclophosphamide 
for treating flares and serious disease[186]. New strategies for managing disease include 
antibody-based treatments targeting inflammatory cytokines, like BAFF, IL-10, and TNFα, 
which drive disease progression[186]. These therapies have shown beneficial effects and are 
still under development[185]. 
The etiology of SLE is still unclear, but it is well-established that patients afflicted are 
genetically predisposed[187] and environmental factors also contribute [188]. Mouse models 
used to study SLE include the MRL
lpr/lpr
 mouse strain[189] which is deficient in Fas[190], 
and thus has a defective apoptotic program in activated B lymphocytes. These mice develop 
high titers of autoantibodies[189], indicating the importance of this pathway in regulating 
autoreactive B cells. In a model of lupus nephritis in mice, it was described that IL-18 had a 
negative role for the induction, prompting further investigation of this cytokine in relation to 
autoimmunity[191].  
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2 THE PRESENT STUDY 
2.1 AIM 
The general aim of the present study was to investigate how innate immune cells regulate B 
cell activation in inflammation and when using novel vaccine adjuvants.  
Specific aims: 
Paper I. To investigate how the B cell response in IL-18-induced antibody production is 
initiated and regulated by iNKT cells. 
Paper II. To investigate how cognate and noncognate iNKT-cell help provided to B cells 
shape ensuing antibody responses. 
Paper III. To identify how iNKT cells and neutrophils collaborate to restrict B cell activation 
induced by sterile inflammation 
Paper IV.  To investigate the possibility of harnessing glycolipid stimulation of iNKT cells in 
order to regulate B cell activation in sterile inflammation 
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Figure 5. Increased serum levels of IgE in iNKT cell-deficient mice (Jα18-/- and CD1d-/-) 
injected with IL-18, compared to wild type mice (left). Increased formation of CD138+ 
extrafollicular foci in the absence of iNKT cells. Immunohistochemistry of spleen sections 
from wild type and CD1d-/- mice pre-immunization (PI) and following injection with IL-18. 
(Scale bar, 150μm) (right) 
 
2.2 RESULTS AND DISCUSSION 
2.2.1 The inflammatory cytokine IL-18 induces self-reactive innate antibody 
responses regulated by natural killer T cells (Paper I) 
Elevated levels of IL-18 have been reported in several autoimmune disorders [174-177]. 
Although originally identified as IFN-inducing factor, IL-18 is a cytokine that enhances 
different types of immune responses depending on the context [171]. If combined with IL-12, 
IL-18 gives rise to a significant IFN production – the archetypical TH1 cytokine, while 
injecting IL-18 alone results in a pronounced TH2 response which depends on IL-4 and IL-
13[172]. While the T cell response in IL-18-mediated inflammation has been extensively 
studied, little was known about how B cells are activated in response to increased levels of 
this cytokine. Thus, we set out to investigate the B cell response in settings of elevated 
systemic levels of IL-18. 
Intraperitoneal injections of IL-18 alone for 10 consecutive days resulted in IgE and IgG1 
production, as well as increased serum levels of IgM. In addition, serum levels of 
autoreactive antibodies were significantly elevated in mice injected with IL-18. Antibody 
levels against NP coupled to bovine serum albumin (BSA) were significantly increased in 
mice injected with IL-18 alone. In summary, these findings indicate an induction of a 
polyclonal natural antibody response. 
To determine the type of B cell activation induced by elevated levels of IL-18, we 
investigated how different B cell populations expanded in response to repeated injections of 
IL-18. We found that mice injected with IL-18 had a transient increase in the innate type 
marginal zone B cell population, peaking at day 6 after induction of inflammation. Later in 
response to elevated levels of IL-18, plasma cells and germinal center B cells populations 
also expanded. These B cell-activating features following IL-18 injections could be mediated 
by the cytokine BAFF [39, 192], of which we found increased levels in serum of mice 
injected with IL-18.  
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iNKT cells restrict GC formation in autoreactive B cell responses[33]. Moreover, in several 
autoimmune diseases where increased levels of IL-18 have been reported, there are 
alterations in the iNKT cell compartment[193]. This prompted us to further investigate the 
role of iNKT cells in regulation of B cell activation induced by IL-18. Injecting iNKT cell-
deficient mouse strains with IL-18 resulted in a significant increase in serum antibody levels 
as compared to wild type. Histological investigation of the B cell activation revealed that 
extrafollicular foci and germinal center formation was increased in iNKT cell-deficient mice.  
In iNKT cell-deficient CD1d-/- mice we found an even more pronounced activation of B 
cells, with increased GC and extrafolicular foci formation, shown by immunohistochemistry. 
By means of quantitative RT-PCR we found that CD1d-/- mice injected with IL-18 had 
higher expression levels of aid, unlike wild type mice  
However, the qualitative changes of the antibody response and whether iNKT cells regulated 
these was still unknown. Therefore, we next used quartz crystal microbalancing (QCM) to 
measure affinity. QCM is a technique similar to surface plasmon resonance, with a difference 
in that it employs the piezoelectric effect, instead of resonant oscillation of conduction 
electrons[194]. We investigated the ability of sera pooled from wild type and CD1d-/- mice to 
bind to carboxylchips coated with the NP-hapten coupled at a low ratio to BSA (NP4-BSA, 
i.e. 4 NP haptens per BSA molecule). Using this approach, we found no difference in the 
capability of pooled sera from wild type mice injected with IL-18 to bind to the high affinity 
NP4-BSA antigen, as compared to pre-immunized controls. However, in pooled sera from 
CD1d-deficient mice, there was increased binding to the high affinity antigen, suggesting a 
qualitative change in the antibody response in the absence of iNKT cells.  
How iNKT cells regulated B cell activation was still unknown. iNKT cells produce and 
respond to IL-21[108], and express higher levels of cytotoxic molecules in response to this 
cytokine[105]. As IL-21 inhibits IgE production[110], we measured expression levels of this 
cytokine and found a significant increase in splenic levels of Il-21 mRNA. Next, we 
examined mice deficient in cytotoxic pathways important in mediating cell death. Perforin 
and FasL (CD178) are two cytotoxic molecules known to be utilized by iNKT cells in a 
CD1d-dependent manner[195]. Injecting IL-18 into strains of mice deficient in perforin or 
FasL resulted in significantly elevated levels of serum IgE compared to wild type controls, 
indicating that these pathways are mechanistically linked to the regulation of B cell antibody 
production in response to elevated levels of IL-18. 
In summary, we found that elevated levels of IL-18 induce B cell activation that results in 
production of self-reactive antibodies. B cell activation is strictly regulated by iNKT cells that 
prevent GC entry and formation of extracellular foci. iNKT cells limit expression of AID and 
the formation of antibodies capable of binding self- and natural antigens.  
Figure 6. Presence of high-affinity anti-NP 
antibodies determined by quartz crystal 
microbalance. Pooled sera from indicated 
groups were tested for binding to NP4-BSA 
immobilized on a carboxyl-chip, detected as 
changes in frequency measured with an 
Attana100  
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2.2.2 Cognate interaction with iNKT cells expands IL-10-producing B 
regulatory cells (Paper II) 
The ultimate goal with a vaccine is to generate immunological memory against harmful 
pathogens, thus generating immunity against future encounters with the same pathogens. 
There are highly efficient vaccines which enabled eradication of previously deadly diseases, 
such as the smallpox vaccine. However, there are still many infectious diseases for which 
there are currently no efficient vaccines, and conventional methods for eliciting protection 
against these harmful infections have proved inefficient. Therefore, much effort has been 
aimed at exploring novel strategies to increase the efficiency and immunogenicity of 
vaccination protocols [196-198].  
iNKT cells stimulated with cognate lipid antigen provide help to B cells, and thus stimulate 
antibody production[108, 109]. Glycolipids that stimulate iNKT cells could function as 
vaccine adjuvants and are therefore attractive compounds in novel vaccine design. iNKT-cell 
help to B cells generates a robust primary antibody response with both cognate and non-
cognate iNKT-cell help. However, cognate iNKT-cell help cannot induce memory B cell 
responses[108, 109]. The fundamental difference in the B cell help delivered by iNKT cells 
activated either in a cognate or noncognate fashion remains elusive. Understanding the 
difference between these types of help provided by iNKT cells to B cells may allow us to 
harness this type of help for future vaccine development. 
To address how cognate iNKT-cell help differs from noncognate, we used two different 
model antigens. First, we immunized mice with a haptenated protein (NP-Keyhole Limpet 
Hemocyanin (KLH)) plus αGalCer, in order to deliver noncognate signals to iNKT cells.  
Second, we used directly haptenated lipid (NPαGalCer) alone, to deliver cognate iNKT cell 
stimulus. Immunizing mice with NPαGalCer alone resulted in a quick, but transient GC 
response. Immunizing mice with NP-KLH plus αGalCer induced more TFH cells and later 
development of germinal center B cells, compared to NPαGalCer alone. Additionally, 
cognate iNKT-cell help induced more TFR cells than noncognate iNKT cell-help. TFR and 
TFH cells are important in negative and positive regulation of GC responses, 
respectively[86]. Thus, higher numbers of TFR cells and lower number of TFH cells following 
cognate iNKT-cell, compared to noncognate, help could potentially contribute to an impaired 
induction of B cell memory. 
The reason for the failure of cognate iNKT-cell help to induce memory B cell responses 
could be that there were too few iNKTFH cells. PD-1 and CD25 are negative regulators of TFH 
development[88, 199]. In order to increase the number of iNKTFH cells, we generated mixed 
Figure 7. Cognate iNKT-cell help preferentially expands innate B-cell populations. 
Splenocyte FACS data from mice immunized with vehicle, 100μg NP-KLH+ 0.5μg αGalCer, 
or 0.5μg NP-αGalCer. Pie charts show B-cell subsets as percentages of total B cells in the 
spleen. 
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bone marrow chimeras deficient in PD-1 or CD25, specifically in iNKT cells. We found that 
these chimeras had increased numbers of iNKTFH cells. However, these mice could still not 
generate B cell memory following immunization with NPαGalCer, indicating that there are 
qualitative differences between cognate and noncognate help from iNKT cells. 
iNKT cells localize in the marginal zone of the spleen following immunization with cognate 
antigen[96]. We therefore investigated how noncognate and cognate iNKT cell help affected 
the expansion of different B cell populations following immunization with NP-KLH plus 
αGalCer or with NPαGalCer alone. We found that cognate iNKT cell help preferentially 
expands innate B cell populations. Both noncognate and cognate iNKT cell help induced an 
expansion of MZB cells, but nocognate iNKT cell help only transiently, and would instead 
support a later germinal center B cell response. Conversely, cognate iNKT cell help induced a 
transient germinal center B cell expansion. Instead cognate iNKT-cell help was able to 
support a MZB cell expansion for a more extended period of time, compared to noncognate 
iNKT-cell help.  
Since cognate iNKT cell help preferentially expanded CD1d
hi
 MZB cells in the spleen, we 
next investigated the difference between cognate and noncognate iNKT cell help regarding a 
related splenic subset of B cells – the regulatory B cells[65]. To this end, we used VertX IL-
10 reporter mice, reports IL-10 production via green fluorescent protein[200]. Following 
immunization of these mice, we found that NPαGalCer induced more antigen-specific B10 
cells compared to NP-KLH plus αGalCer, and that higher numbers of these cells were IL-10 
positive. However, cognate iNKT cell help is not specifically focused on the induction of IL-
Figure 8. Cognate iNKT-cell help expands antigen-specific IL-10+ B10 B cells. FACS data 
of splenocytes 4d after immunization with vehicle, NP-KLH+αGalCer, or NPαGalCer. FACS 
analysis showing B220+NP+(A and B), B220+NP+CD1d+CD5+(C and D), and 
B220+NP+CD1d+CD5+IL-10+(E and F) subsets of cells. 
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10-secreting B cells, since the proportion of IL-10+ B cells expanded in the antigen-specific 
CD5+CD1d+ B regulatory cell population is lower, rather than higher in mice immunized 
with NPαGalCer.  
This feature of cognate iNKT cell help provided to B cells - generating a higher number of 
regulatory B cells - might explain the different outcomes regarding memory B cell formation 
following cognate and noncognate iNKT cell help. 
In conclusion, there are fundamental qualitative and quantitative differences between cognate 
and noncognate iNKT cell help provided to B cells. Cognate iNKT cell help provided to B 
cells fails to generate B cell memory, possibly due to differences in B and T cell activation 
induced by cognate iNKT cell help as compared to noncognate. These findings have 
implications for the design of vaccines employing glycolipids as adjuvants, indicating that the 
way signals are delivered will affect the outcome in terms of B cell memory.  
2.2.3 Neutrophils license iNKT cells to regulate self-reactive B cell 
responses (Paper III) 
In paper I, we found increased levels of BAFF, a cytokine crucial to activation of B 
cells[201]. Therefore, we investigated potential sources of BAFF. Many cells are capable of 
producing BAFF, including DCs, macrophages and neutrophils[131]. Employing our 
inflammatory model with daily i.p. injections of IL-18, we investigated the kinetics of the 
systemic increase in BAFF and found that serum BAFF levels were significantly increased 
four days following injections of IL-18. Neutrophils stimulate B cells by producing BAFF 
and provide help to innate type B cells [123]. Neutrophils are thus potential candidate cells 
involved in controlling B cell activation in response to increased systemic levels of IL-18. 
Neutrophils accumulate in the spleens of mice injected with IL-18 compared to vehicle-
injected controls. We investigated the presence of IL-18R on splenic neutrophils and found 
that they express this receptor, indicating that elevated levels of IL-18 could influence splenic 
accumulation of neutrophils directly. We cultured sorted neutrophils in vitro in the presence 
of IL-18 and identified an increase in the surface expression of BAFF. Array data of sorted 
splenic neutrophils from mice injected with IL-18 showed that neutrophils upregulate 
Tnfsf13b mRNA following elevated systemic levels of IL-18. Additionally, splenic 
neutrophils expressed BAFF on their surface. 
In paper I, we found that iNKT cells negatively regulate B cell activation. The splenic 
accumulation of neutrophils identified here prompted us to investigate the expression of 
CD1d on these cells. Expression of CD1d is a requirement for cognate engagement of iNKT 
cells[92]. At steady state, splenic neutrophils did not express detectable CD1d on the cell 
surface. However, sorted neutrophils exposed to IL-18 in vitro upregulated cell surface 
CD1d.  
CXCR6+ is a chemokine receptor expressed almost exclusively by iNKT cells in the spleen 
[95, 96]. Therefore, we used CXCR6-GFP knock-in mice to address if iNKT cells and 
neutrophils were located close enough to permit interaction. In the spleens of these mice we 
found numerous examples of CXCR6+ iNKT cells in close proximity to neutrophils in the 
splenic red pulp.  
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Neutrophils and iNKT cells can potentially communicate in several different ways, as both 
cells express many different cytokines[105, 115], and cell surface receptors known to 
interact, for instance CD40-CD40L[109, 202]. However, since we found that IL-18 induced 
CD1d on neutrophils in vitro, we first address the prospect of cognate interaction between 
neutrophils and iNKT cells. Using mixed bone marrow chimeras we detected an upregulation 
of CD1d in response to injections with IL-18, enabling cognate interaction with iNKT cells in 
vivo (Figure 9). Strikingly, CD1d-deficient neutrophils had a compromised ability to induce 
an activated phenotype in response to elevated levels of IL-18. This suggests that cognate 
interaction between iNKT cells and neutrophils is required in order for neutrophils to be fully 
activated in IL-18-mediated inflammation.  
Next, we investigated phenotypic changes of iNKT cells and found that iNKT cells, 
specifically, upregulated FasL following injections with IL-18 (Figure 9). Since neutrophils 
upregulated CD1d in response to IL-18, we tested whether the presence of neutrophils had 
any impact on the expression of FasL by iNKT cells. By means of antibody-dependent 
cellular cytotoxicity (ADCC) - using antibodies to selectively deplete neutrophils – we found 
that FasL upregulation was abrogated in mice with elevated IL-18-levels depleted of 
neutrophils. Thus, neutrophils license iNKT cells to adopt a killing phenotype.  
We next sought to establish whether FasL expressed specifically by iNKT cells was required 
to control faulty B cell activation leading to autoantibody production. Using mixed bone 
marrow chimeric mice, we found that mice reconstituted with FasL-deficient iNKT cells had 
significant increases in the proportion of plasma cells as well as germinal center B cells. 
However, mice receiving wild type iNKT cells were able to control expansion of these B cell 
subsets. These differences were reflected in the serum levels of anti-DNA IgG1 and IgG3 
(Figure 10). Mice receiving wild type iNKT cells showed no differences in serum levels of 
autoantibodies in response to increased levels of IL-18. However, mice receiving FasL-/- 
iNKT cells had an increase in both serum anti-DNA IgG1 and IgG3. Thus, iNKT cells 
transferred in these experiments blocked B cell activation and self-reactive antibody 
formation using FasL. 
Figure 9. CD1d expression by neutrophils in mixed bonew marrow chimeras and iNKT cell 
expression of FasL following depletion of neutrophil using the antibody 1A8. Expression of 
CD1d measured by FACS, following exposure to IL-18 in vivo in neutrophils derived from 
the indicated genetic background (left).Normalized FasL expression by iNKT cells harvested 
from spleens of mice injected with vehicle, IL-18, neutrophil-depleting 1A8 antibody, or 1A8 
+ IL-18 (right). 
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B cells could potentially be regulated by more than just FasL, considering that some B cell 
subsets express very high levels of CD1d[33]. In paper I, we established that B cells enter 
germinal centers in response to elevated levels of IL-18. Therefore, we used mixed bone 
marrow chimeras to investigate how CD1d expression by B cells affected the propensity to 
form germinal centers. We found that germinal center B cell formation was significantly 
increased in the population of B cells lacking CD1d. This indicates that iNKT cells directly 
interact with B cells in a cognate fashion in order to restrict this type of B cell activation. In 
order to test if iNKT cells moved to germinal centers to exert this regulation, we injected the 
CXCR6-GFP knock-in mice with IL-18. Surprisingly, we could detect no increase in the 
density of iNKT cells in germinal center areas of the spleen on day 12 in mice injected with 
IL-18 compared to controls. However, in CD138+ extrafollicular foci, there was a significant 
increase in the density of iNKT cells. This suggests that iNKT cells redistribute to 
extrafollicular foci following increased levels of IL-18. However, iNKT cells could also be 
present at higher densities in the GC, earlier in the response. 
We next investigated how a lack of neutrophils available to license iNKT cells affected B cell 
activation in response to increased levels of IL-18. We found that AFC and GC responses 
increased in the spleens of neutrophil-depleted mice injected with IL-18, compared to IL-18 
alone. This suggested that the presence of neutrophils was required to restrict B cell 
activation. The lost restriction of B cell activation seen in neutrophil-depleted mice injected 
with IL-18 also had significant effects on the serum levels of self-reactive antibodies. Serum 
levels of anti-DNA IgG1 and IgG3 increased compared to mice injected with IL-18 alone. 
This indicated that the presence of neutrophils which license iNKT cells to restrict faulty B 
cell activation is essential to keep the levels of autoreactive antibodies in check.  
In conclusion, in paper III we have identified a previously unappreciated crosstalk between 
iNKT cells and neutrophils in sterile inflammation. Neutrophils were required in order to 
license iNKT cells to adopt a killing phenotype in response to elevated systemic levels of IL-
18, and this was critical to restrict faulty B cell activation and the production of autoreactive 
antibodies. Thus, the findings in paper III suggest mechanisms potentially underlying 
autoimmune disease. 
Figure 10. Increased serum levels of autoantibodies in mice with an iNKT-cell specific 
FasL-deficiency. Serum levels of anti-DNA IgG1 and IgG3 in mice reconstituted with wild 
type iNKT cells (left). Serum levels of anti-DNA IgG1 and IgG3 in mice reconstituted with 
FasL-/- iNKT cells (right).  
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2.2.4 Exogenous glycolipid agonists alter the inherent B cell regulatory 
function of iNKT cells (Paper IV) 
Given the different roles played by iNKT cells, we tested the potential of harnessing the 
activity of iNKT cells to redirect faulty immune activation in sterile inflammation in paper 
IV. To this end, a combinatory model was employed where inflammation was induced by 
daily intraperitoneal injections with IL-18 combined with one injection of glycolipid iNKT 
cell ligand at onset of inflammation, at the time of the first injection of IL-18.  
Total serum levels of IgE and IgG1 increase in response to intraperitoneal injections of IL-18. 
Compared to IL-18 alone, serum antibody levels were significantly increased when iNKT 
cells were simultaneously stimulated with the iNKT cell ligands OCH[103], GSL-1[102] or 
αGalCer[101]. The formation of autoreactive antibodies of the IgE and IgG1 isotypes also 
increased significantly when activating glycolipids were coadministered with IL-18. 
In paper I, we found that the MZB cell population expanded in response to elevated levels of 
IL-18. Therefore we investigated changes in B cell proportions and phenotypes in response to 
IL-18 plus glycolipid. We found no differences in the proportion of MZBs with glycolipid 
and IL-18 combined, while MZB expression of CD1d was significantly increased in response 
to IL-18 alone. However, when αGalCer was administered concomitantly with IL-18, the 
increase in CD1d expression following IL-18 alone was abrogated. The proportion of plasma 
cells in the spleen significantly increased in response to IL-18 alone and was even higher 
when OCH was co-administered. The frequency of germinal center B cells was increased in 
response to IL-18 alone, and all the activating glycolipids tested, further enhanced the 
proportion of germinal center B cells. We next investigated the switching patterns exerted by 
plasma cells and found that αGalCer combined with IL-18 resulted in significantly increased 
proportions of plasma cells switching to IgE and IgG1.  
Figure 11. Increased serum IgE levels in wild type mice receiving glycolipids in 
inflammation. Injection of OCH, αGalCer (αGC), and GSL-1 into wild type mice receiving 
IL-18, all result in increased production of IgE, compared to IL-18 alone. 
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Next, we investigated the proportion of iNKT cells. We found that, as has been reported 
before, the iNKT cell proportion was significantly diminished in response to injection with 
αGalCer alone[203]. However, when αGalCer was co-administered with IL-18 there was no 
change in the proportion of iNKT cells in the spleen. Several phenotypic changes following 
activation of iNKT cells have been reported [98, 107, 109]. Therefore, we next investigated 
phenotypic changes in the iNKT cell population and found that αGalCer was a highly potent 
inducer of the CXCR5+ PD-1+ iNKTFH phenotype. Additionally, a pronounced population of 
KLRG1+ iNKT cells formed when injecting αGalCer, with or without IL-18. 
iNKTFH cells provide help to B cells in immune responses so as to boost antibody 
production[108, 109]. The dramatic change seen in the iNKT cell population of mice 
immunized with αGalCer with or without IL-18 might in part explain the differences seen in 
serum antibody levels seen compared to controls in these different treatment groups. The 
induction of iNKTFH cells in the iNKT cell population could potentially lead to B cell-helping 
functions being activated in iNKT cells. This could in turn lead to increased stimulatory 
cytokine production by iNKT cells enabling B cell activation and antibody production[204]. 
The induction of KLRG1+ iNKT cells is interesting with respect to the antitumor activity 
reported in this subset of iNKT cells[98]. It seems like IL-18 could be able to induce an even 
higher proportion of KLRG1+ iNKT cells than αGalCer alone. While more experiments are 
required to address this, it certainly would be interesting to use IL-18 as an adjuvant to 
αGalCer in the generation of antitumor memory iNKT cells. 
Our discovery in paper III that neutrophils upregulated prompted us to investigate how the 
administration of glycolipids in addition to IL-18 affected neutrophils and BAFF. We found 
that the only lipid with significant effects by itself was αGalCer, which induced a significant 
accumulation of splenic neutrophils. In combination with IL-18, there was a combinatory 
effect of IL-18 and αGalCer, so that the proportion of neutrophils increased compared to IL-
18 or αGalCer alone, respectively. Although GSL-1 and OCH did not affect the proportion of 
neutrophils when administered alone, OCH in combination with IL-18 significantly increased 
Figure 12. iNKT cell phenotype following glycolipid stimulation of iNKT cells in 
inflammation. Representative FACS plots indicating expression of iNKTFH-markers PD1 
and CXCR5 in population gated according to left panel. Percentages indicate frequency of 
parent. 
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the number of neutrophils present in the spleen, compared to OCH or IL-18 alone, 
respectively. Following IL-18 injections, adding activating iNKT cell ligands induced 
elevated levels of the cytokine BAFF. Since we established in paper III that IL-18 is capable 
of directly inducing BAFF expression by neutrophils, the increase in serum BAFF in mice 
injected with IL-18 plus αGalCer could possibly be explained by the increased accumulation 
of neutrophils in the combined treatment group, compared to IL-18 alone.  
In conclusion, the activation of iNKT cells in inflammation using glycolipids results in an 
increase in B cell activation and production of autoreactive antibodies. Thus, in a setting of 
autoinflammatory disorders involving IL-18, different glycolipid administration protocols 
should need to be investigated further for their capacity to skew antibody production.  
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2.2.5 Concluding remarks and future perspectives 
The major findings of the work presented in this thesis are: 
 Increased systemic levels of IL-18 lead to the activation of autoreactive B cells. This 
activation is restricted by iNKT cells 
 Differences between cognate and noncognate iNKT cell help to B cells depend on 
qualitatively and quantitatively diverse responses 
 In inflammation, iNKT cells are licensed by neutrophils to adopt a regulatory 
phenotype required to restrict autoreactive B cells 
 Glycolipid agonists of iNKT cells affects production of antibodies in inflammation 
Many conclusions in this thesis are based on experiments involving injections of large 
amounts of IL-18. The amounts of IL-18 used in experiments will rarely be achieved in a 
physiological or even pathological setting. In an adult person afflicted with sepsis, amounts of 
up to 10ng of IL-18 per milliliter serum have been reported[168]. Therefore, the model of 
elevated systemic levels of IL-18 serves a highly relevant purpose in demonstrating essential 
effects of IL-18 in vivo.  
The work in paper I identified iNKT cells as negative regulators of self-reactive B cell 
responses and autoantibody production in settings of increased levels of IL-18. As the levels 
of IL-18 are increased in several autoimmune diseases, IL-18 neutralization could potentially 
be a target for therapeutic intervention. Clinical trials are underway, testing the potential for 
the investigational drug Tadekinig alfa (recombinant IL-18BP) in order to treat the 
inflammatory adult-onset Still’s disease. In adult-onset Still’s disease, high levels of IL-18 are 
thought to play a critical role in pathogenesis. Thus, supplementing the body with an 
endogenously available regulator of IL-18 might prove beneficial in disease where this 
cytokine causes pathology. Phase 1 clinical trials have proven safety, although side effects 
remain to be investigated. Potentially, side effects of blocking IL-18 could include obesity 
and insulin resistance, as IL-18-/- mice present with these phenotypes[205]. The function of 
IL-18 in priming immune responses against tumors is also a factor to consider for IL-18-
blocking therapies. Il-18 depletion could possibly lead to increased tumor progression, while 
the opposite is also true, due to the context-dependent functions of this cytokine[206]. 
In paper III, we found that part of the mechanism by which iNKT cells negatively regulate 
autoreactive B cell activation is through a change in phenotype. In response to IL-18, iNKT 
cells increase the expression of molecules mediating cellular cytotoxicity, in this case FasL. 
The conditional knock-out of FasL specifically on iNKT cells, resulted in increased 
production of autoreactive antibodies, but other molecules involved in cytotoxicity could also 
be involved. When Perforin-deficient mice were injected with IL-18 (paper I), serum levels of 
IgE were significantly increased compared to controls. Thus, it would be highly relevant to 
also investigate this molecule in the regulation of faulty B cell activation in response to IL-18, 
and specifically, whether iNKT cells make use of this pathway. However, the potential 
receptors employed by iNKT cells for regulating cell populations through killing seems to not 
be redundant, as knocking out FasL alone in the iNKT cell population still results in a 
significant B cell activation not permitted in mice with FasL-proficient iNKT cells. Possibly, 
the different killing pathways are used in different contexts. It has been suggested that 
antigenic potency correlates with in vivo cytotoxicity mediated by iNKT cells[195]. 
However, signals other than TCR strength are likely to be involved, as iNKT cells are 
activated by cytokines as well as other receptors [97]. Were it possible to pharmacologically 
induce a killing phenotype in iNKT cells, it might be possible to restore cytotoxic functions 
and thus restrict faulty B cell activation in autoimmune disorders. However, IL-18 might have 
too pleiotropic effects in order to be a candidate. 
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The reason for failure to restrict B cell activation might in part depend on neutropenia, which 
is found in about one-half of SLE patients[207]. As we found that the presence of neutrophils 
is required in order to license iNKT cells to adopt a killing phenotype, this could explain 
mechanisms underlying SLE. This finding also holds promise as a target for future 
therapeutic approaches. Inducing normal neutrophil numbers in combination with stimulating 
a killing phenotype by iNKT cells at the same time might be effective in re-establishing 
restriction of B cell activation in antibody-mediated diseases. This could be achieved by 
means of neutropoiesis-stimulating cytokines like GM-CSF or G-CSF. It has been reported 
that GM-CSF protects neutrophils against apoptosis[208], and this could be a highly desirable 
effect. Dead or dying neutrophils potentially provide self-antigens, thus propagating disease 
[138]. However, as many patients do not present with neutropenia, even complete success of 
these hypothetical treatments will probably not be able to cure all patients. There is also the 
caveat that comes with BAFF provision by neutrophils. Possibly, G-CSF would generate 
more neutrophils able to deliver BAFF, thus exacerbating disease.  
In paper II we identified fundamental differences between cognate and noncognate iNKT cell 
help to B cells that have important implications for future vaccine design. Glycolipids which 
stimulate iNKT cells, boosting desirable immune responses hold great promise as compounds 
that can be used as adjuvants for new vaccines. We found an increase in IL-10 expressing B 
cells following cognate iNKT-cell help. Recently, iNKT cells were described to produce the 
inflammation-dampening cytokine IL-10 following a pre-activation protocol with αGalCer, 
showing that stimulation with iNKT cell ligands does not necessarily result in amplification 
of immune responses[107]. The reason why cognate iNKT-cell help to B cells fails to 
generate a robust memory response still remains partly unsolved. Potentially, the signals 
generated following cognate stimulation are too strong, therefore leading to an induction of 
IL-10 production by B cells. This would be analogous to the induction of IL-10 iNKT cells, 
where a strong induction leads to a regulatory phenotype, thus innate B cells mirroring the 
behavior of innate T cells. Since CD1d-expressing B cells and iNKT cells both are enriched 
for self-reactivites, cognate iNKT-cell help generating memory efficiently, could be a 
highway to autoimmunity. iNKT cell-stimulating glycolipids potentially cause unwanted 
activation of B cells in settings of autoimmune disease, as indicated by findings from paper 
IV.  
In paper IV we tested the possibility of skewing the inflammatory response following 
elevated levels of IL-18 by means of glycolipid iNKT cell agonists. The iNKT cell regulatory 
role established in paper I, and the underlying mechanisms identified in paper III, prompted 
us to test different iNKT cell ligands in our inflammation model. However, when injecting a 
bolus dose of glycolipid at the beginning of inflammation onset, the levels of antibodies and 
B cell activation actually increased. Future studies should make use of several different 
glycolipid administration protocols, maybe similar to Sag et al.[107],as this has profound 
implications on how iNKT cells respond.  
All studies in this thesis were performed using mouse models and mouse-derived cells, in 
vivo and in vitro. This forms a caveat, since different types of antigen-presenting molecules 
exist in mouse and man. While mice only express CD1d, humans express several different 
CD1 molecules able to present a wider array of antigens[93]. Thus, there is a potential loss in 
translation. However, a significant part of the iNKT cell repertoire in humans is able to bind 
antigens which typically are used to define murine iNKT cells. Thus, studies performed in 
mice have without question generated new insights concerning the biology of iNKT cells, 
which are currently applied even in clinical trials involving compounds first investigated in 
mice. 
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Taken together, the work presented in this thesis expands our knowledge about how B cell 
activation is regulated in inflammation, and how the activation of B cells can be 
fundamentally different depending on how helping signals are delivered.  
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